The anticipated size of the prophylactic HIV drugs market in 2022 was US$ 31,278.5 million and is estimated to be US$ 32,516.1 million in 2023.
Growth in the market is mainly due to an increase in research and development through investment in HIV clinical trials of pharmaceutical and biotechnology companies, increasing drug approvals for HIV, and a rise in the incidence of HIV in the population. According to Future Market Insights estimation, the market is predicted to expand at a CAGR of 4.1% between 2023 and 2033, totaling around US$ 48,822.4 million by 2033.
The global prophylactic HIV drugs market size reached a valuation of around US$ 30 billion in 2021. Due to the rising prevalence of HIV infection worldwide and growing awareness about HIV AIDS prevention, the demand for prophylactic HIV drugs registered a 4% CAGR between 2022 and 2032, totaling over US$ 40 billion in 2028.
Human immunodeficiency virus (HIV) has become one of the leading causes of death worldwide affecting millions of people. The virus targets the immune system of infected patients and makes them vulnerable to many infections and cancers.
The condition can be managed through increasing access to effective prevention, diagnosis, treatment, and care although there is no permanent cure available for HIV infection. The rising focus on preventing the acquisition of HIV is one of the key factors pushing the demand for prophylactic HIV drugs.
Prophylactic HIV drugs are advanced therapeutics used to prevent getting HIV infection in certain circumstances as they have been especially effective in preventing the acquisition of HIV from sex and injection drug use.
Amid the rising prevalence of HIV, people across the world are showing a keen inclination toward consuming pre-exposure prophylaxis (PrEP) due to its better effectiveness. According to the Centers for Disease Control and Prevention (CDC), PrEP reduces the risk of getting HIV from sex and injection drug use by around 99% and 74% respectively.
Prophylactic HIV drugs such as antiretroviral (ARV) are gaining immense popularity due to their ability to prevent and control HIV infection. Additionally, growing awareness among people regarding HIV and the benefits of prophylactic HIV drugs might continue to boost the sales of prophylactic HIV drugs during the forecast period.
| Attributes | Details |
|---|---|
| Projected Forecast Value (2022) | US$ 31,278.5 million |
| Projected Forecast Value (2023) | US$ 32,516.1 million |
| Projected Forecast Value (2033) | US$ 48,822.4 million |
| Growth rate | 4.1% CAGR |
| Forecast period | 2023 to 2033 |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global prophylactic drugs market expanded at a CAGR of 3.5% between 2018 and 2022. Growth forecasts remain optimistic, with the market predicted to exhibit a CAGR of 4.1% between 2023 and 2033.
Future growth of the market is estimated to boost by initiating various potential pipeline candidates like fostemsavir and PRO 140 by the drivers of generic versions of various branded drugs such as tenofovir disoproxil fumarate tablets.
Rise in HIV Cases Worldwide
The notable surge in HIV cases worldwide, continuous novel drug launches and approvals, and the increasing need for preventing and controlling HIV are some of the major factors stimulating the growth of the prophylactic HIV drugs market.
Prophylactic HIV drugs have become highly sought-after therapeutics for preventing the acquisition of HIV infection among people who are at high risk. Consumption of these drugs significantly reduces the chances of HIV infection. They are mostly recommended during sex and injection drug use where there is a high chance of HIV transmission.
The growing popularity of prophylactic HIV drugs on account of their better effectiveness and cost-effective nature is providing a strong thrust to the growth of the prophylactic HIV drugs market and the trend is likely to continue during the forecast period.
The increasing prevalence of HIV and its high mortality rate are pushing the demand for therapeutics like prophylactic HIV drugs. According to the World Health Organization (WHO), there were around 1.5 million newly infected cases of HIV and over 680000 deaths in 2020. This is prompting people to use prophylactic HIV drugs.
Increasing government initiatives and investments in spreading awareness among people about HIV, its symptoms, precautions, and treatment are expected to further expand the prophylactic HIV drug market size during the forecast period.
Principal Consultant
Side Effects Associated with Prophylactic HIV Drugs
Certain obstacles are challenging the growth of the prophylactic HIV drugs market despite its optimistic stance. Some of these obstacles include side effects associated with prophylactic HIV drugs, strict government approval for these drugs, and low awareness levels about these therapeutics across low emerging economies.
It has been observed that prophylactic HIV drugs often lead to side effects such as headache, depression, nausea, vomiting, abdominal pain, etc. Many people refrain from consuming these therapeutics. This in turn is limiting the growth of the prophylactic HIV drugs market.
Growth in North America Prophylactic HIV drugs market
According to FMI analysis, North America is likely to retain its dominant position in the global prophylactic HIV drugs market with a value share of 41.7%, accounting for a significant market share. Moreover, growth in North America's prophylactic HIV drugs market is underpinned by the presence of a high level of awareness among people, the surge in HIV infection cases, the availability of advanced healthcare facilities, and the growing adoption of new therapeutics.
Demand for prophylactic HIV drugs is especially rising across countries like the United States and Mexico due to a surge in HIV cases. The rapid surge in cases of HIV infection in the United States holds a value share of 36.9% resulting in the rising incidences of unprotected sex and the use of unsterile injections. Moreover, there were around 34800 new HIV infection cases reported in the USA. The rise in HIV infection cases is playing a key role in pushing the growth of the prophylactic HIV drugs market.
The Rising Prevalence of HIV Infection and Increasing Adoption of Novel Therapeutics
Amid the rising prevalence of HIV infection and increasing adoption of novel therapeutics, Europe's prophylactic HIV drugs market is likely to expand at a CAGR of 28% with a considerable pace during the forecast period.
Sharp rise in cases of HIV in countries of Europe like the United Kingdom expanding at a CAGR of 5.0%. As per the European Centre for Disease Prevention and Control, over 2.2 million people have been diagnosed and reported with HIV in the Europe Region according to WHO during the last three decades. This in turn is fostering the growth of the prophylactic HIV drugs market in the region. Further, the presence of leading manufacturers such as ViiV Health is positively impacting the growth of the prophylactic HIV drugs market across Europe.
Introduction of Public Health Intervention for Minimization of HIV Transmission
Pre-exposure prophylaxis (PrEP) in China, is a newly introduced public health intervention for minimizing HIV transmission, where the coverage has remained limited expanding at a CAGR of 5%. Best delivery models and strategies for broadening access to vulnerable communities are not fully known.
Reviews have identified that PrEP programs reporting in India expanding at a CAGR of 4.1% were differentiated by delivery models that are accompanied by a healthcare accessibility framework.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Prophylactic HIV Drugs Market:
| Attributes | Prophylactic HIV Drugs Market |
|---|---|
| CAGR (2023 to 2033) | 4.1% |
| Market Value 2023 | US$ 32,516.1 million |
| Growth Factor | Non-profit organizations and pharmaceutical and biotechnology companies are investing more in HIV clinical research, which in turn boosts the growth of the market. |
| Future Opportunities | Prominent manufacturers of the drugs present in the global market are striving ardently for conducting extensive research and development activities to introduce new products. |
| Market trends | The growing popularity of prophylactic HIV drugs on account of their better effectiveness and cost-effective nature is providing a strong thrust to the growth of the prophylactic HIV drugs market |
HIV Drugs Market:
| Attributes | HIV Drugs Market |
|---|---|
| CAGR (2023 to 2033) | 6.9% |
| Market Value 2023 | US$ 34,300 million |
| Growth Factor | Change in growth trend is mainly because the companies mainly balance their output after arranging the demand that grew exponentially. |
| Future Opportunities | An increase in emphasis on research and development activities in the field of HIV drugs is anticipated for the results that lead to the rise in drug innovations worldwide. |
| Market trends | A rise in awareness among people due to the diagnosis and treatment of HIV disease acts as a key driver acting as growth for the HIV drug market. |
Injectable Drugs Market:
| Attributes | Injectable Drugs Market |
|---|---|
| CAGR (2023 to 2033) | 6.2% |
| Market Value 2023 | US$ 52,239 million |
| Growth Factor | The increase in the burden of infectious diseases, oncology diseases, and cardiovascular diseases is raising the demand for effective treatment solutions across the globe, which is anticipated to boost sales. |
| Future Opportunities | Significant extension in the pharmaceutical sector might fuel sales of the injectable drugs market. |
| Market trends | The proportion of drugs in the pipeline that requires injectable administration has increased due to the rise in the production and availability of biological drugs in the global healthcare market. |
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI) are Considered to have a Dominant Position in the Market
NRTIs are likely to hold a dominant position with a value share of 53.90%as it is mainly helpful if a person is pregnant or has other health conditions other than HIV.
NRTI mainly works by preventing the virus from further multiplying in the body. For example - HIV mainly, NRTIs work by blocking the reverse transcriptase, the enzyme that HIV needs to replicate itself.
Hospital Pharmacies are Preferred the Most in the Market
Hospital Pharmacies significantly hold a value share of 56.50% as people suffering from such a disease are likely to get cured in hospital pharmacies provided with proper treatment facilities.
Some of the prominent players operating in the global market are-
Notable Developments of the Key Players in the Market
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 4.1% from 2023 to 2033 |
| Market value in 2023 | US$ 32,516.1 million |
| Market value in 2033 | US$ 48,822.4 million |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | US$ million for Value and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization Scope | Available on Request |
The prophylactic HIV drugs market is set to attain a value of US$ 32,516.1 million in 2023.
The prophylactic HIV drugs market is estimated to surpass US$ 48,822.4 million by 2033.
The prophylactic HIV drugs market is projected to experience a CAGR of 4.1% through 2033.
North America's prophylactic HIV drugs market holds substantial revenue prospects, capturing a 41.7% value share.
With a commanding value share of 53.90%, the NRTI segment secures the top position in the prophylactic HIV drugs market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Producers 3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) & Volume (Tons) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI) 5.3.2. Integrase Inhibitor 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distributional Channel 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By Distributional Channel, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By Distributional Channel, 2023 to 2033 6.3.1. Hospital Pharmacies 6.3.2. Retail Pharmacies 6.3.3. Mail Order Pharmacies 6.3.4. Drug Stores 6.4. Y-o-Y Growth Trend Analysis By Distributional Channel, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Distributional Channel, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Western Europe 7.3.4. Eastern Europe 7.3.5. South Asia and Pacific 7.3.6. East Asia 7.3.7. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. U.S. 8.2.1.2. Canada 8.2.2. By Drug Class 8.2.3. By Distributional Channel 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Drug Class 8.3.3. By Distributional Channel 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Drug Class 9.2.3. By Distributional Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Class 9.3.3. By Distributional Channel 9.4. Key Takeaways 10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. U.K. 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Western Europe 10.2.2. By Drug Class 10.2.3. By Distributional Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Distributional Channel 10.4. Key Takeaways 11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Poland 11.2.1.2. Russia 11.2.1.3. Czech Republic 11.2.1.4. Romania 11.2.1.5. Rest of Eastern Europe 11.2.2. By Drug Class 11.2.3. By Distributional Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Distributional Channel 11.4. Key Takeaways 12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Bangladesh 12.2.1.3. Australia 12.2.1.4. New Zealand 12.2.1.5. Rest of South Asia and Pacific 12.2.2. By Drug Class 12.2.3. By Distributional Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Distributional Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Drug Class 13.2.3. By Distributional Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Distributional Channel 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Drug Class 14.2.3. By Distributional Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Distributional Channel 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. U.S. 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Drug Class 15.1.2.2. By Distributional Channel 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Drug Class 15.2.2.2. By Distributional Channel 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Drug Class 15.3.2.2. By Distributional Channel 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Drug Class 15.4.2.2. By Distributional Channel 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Drug Class 15.5.2.2. By Distributional Channel 15.6. U.K. 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Drug Class 15.6.2.2. By Distributional Channel 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Drug Class 15.7.2.2. By Distributional Channel 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Drug Class 15.8.2.2. By Distributional Channel 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Drug Class 15.9.2.2. By Distributional Channel 15.10. Poland 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Drug Class 15.10.2.2. By Distributional Channel 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Drug Class 15.11.2.2. By Distributional Channel 15.12. Czech Republic 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Drug Class 15.12.2.2. By Distributional Channel 15.13. Romania 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Drug Class 15.13.2.2. By Distributional Channel 15.14. India 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Drug Class 15.14.2.2. By Distributional Channel 15.15. Bangladesh 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Drug Class 15.15.2.2. By Distributional Channel 15.16. Australia 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Drug Class 15.16.2.2. By Distributional Channel 15.17. New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Drug Class 15.17.2.2. By Distributional Channel 15.18. China 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Drug Class 15.18.2.2. By Distributional Channel 15.19. Japan 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Drug Class 15.19.2.2. By Distributional Channel 15.20. South Korea 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Drug Class 15.20.2.2. By Distributional Channel 15.21. GCC Countries 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Drug Class 15.21.2.2. By Distributional Channel 15.22. South Africa 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2022 15.22.2.1. By Drug Class 15.22.2.2. By Distributional Channel 15.23. Israel 15.23.1. Pricing Analysis 15.23.2. Market Share Analysis, 2022 15.23.2.1. By Drug Class 15.23.2.2. By Distributional Channel 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Drug Class 16.3.3. By Distributional Channel 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Gilead Sciences, Inc 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.1.5.2. Product Strategy 17.1.1.5.3. Channel Strategy 17.1.2. Merck Sharp & Dohme Corp. 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.2.5.2. Product Strategy 17.1.2.5.3. Channel Strategy 17.1.3. Merck & Co. Inc. 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.3.5.2. Product Strategy 17.1.3.5.3. Channel Strategy 17.1.4. Mylan NV 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.4.5.2. Product Strategy 17.1.4.5.3. Channel Strategy 17.1.5. Cipla Inc. 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.5.5.2. Product Strategy 17.1.5.5.3. Channel Strategy 17.1.6. Genentech Inc. 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.6.5.2. Product Strategy 17.1.6.5.3. Channel Strategy 17.1.7. Bristol-Myers Squibb Company 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.7.5.2. Product Strategy 17.1.7.5.3. Channel Strategy 17.1.8. Johnson & Johnson Health Care Systems Inc 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.8.5.2. Product Strategy 17.1.8.5.3. Channel Strategy 17.1.9. Pfizer Inc. 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.9.5.2. Product Strategy 17.1.9.5.3. Channel Strategy 17.1.10. GalaxoSmithKline PLC 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.10.5.2. Product Strategy 17.1.10.5.3. Channel Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Prophylactic HIV Drugs Market
